title: A double-blind, randomised- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea.
abstract: The efficacy and safety of sildenafil was evaluated in a randomiSed, double-blind, placebo-controlled, flexible-dose study in Korean men aged 28-78 y with erectile dysfunction (ED) of broad-spectrum aetiology and more than 6 months duration. A total of 133 patients were randomised at six centres in Korea to receive either sildenafil (50 mg initially, increased if necessary to l00 mg or decreased to 25 mg depending on efficacy and tolerance) (n=66) or matching placebo (n=67) taken on an 'as needed' basis l h prior to anticipated sexual activity for a period of 8 weeks. At the end of this time, the primary efficacy variables relating to the achievement and maintenance of erections sufficient for sexual intercourse, and the secondary efficacy variables, which included: (1) the five separate domains of sexual functioning of the International Index of Erectile Function (IIEF) scale, (2) the percentage of successful intercourse attempts, and (3) a global assessment of erections, were all statistically significantly improved by sildenafil in comparison with placebo (P&<0.0001). Treatment-related adverse events occurred in 56.1% of patients receiving sildenafil and 20.9% receiving placebo. The most common adverse events with sildenafil were vasodilatation (flushing), headache and abnormalities in colour vision (31.8, 22.7 and 6.1% of patients, respectively), and most were mild in nature. The efficacy and safety of sildenafil in this population of Korean men appears similar to that reported in other studies in western populations.
authors.affiliation: Department of Urology, Yonsei University Hospital, Korea. ssclinic@yumc.yonsei.ac.kr
authors.forename: H K
authors.initials: HK
authors.lastname: Choi
authors.forename: T Y
authors.initials: TY
authors.lastname: Ahn
authors.forename: J J
authors.initials: JJ
authors.lastname: Kim
authors.forename: S C
authors.initials: SC
authors.lastname: Kim
authors.forename: J S
authors.initials: JS
authors.lastname: Paick
authors.forename: J K
authors.initials: JK
authors.lastname: Suh
authors.forename: H S
authors.initials: HS
authors.lastname: Kim
authors.forename: Y K
authors.initials: YK
authors.lastname: Kim
authors.forename: W H
authors.initials: WH
authors.lastname: Lee
authors.forename: B H
authors.initials: BH
authors.lastname: Oh
authors.forename: C H
authors.initials: CH
authors.lastname: Park
authors.forename: W S
authors.initials: WS
authors.lastname: Ryu
authors.forename: T G
authors.initials: TG
authors.lastname: Chung
authors.forename: S W
authors.initials: SW
authors.lastname: Kim
authors.forename: W H
authors.initials: WH
authors.lastname: Lee
authors.forename: D G
authors.initials: DG
authors.lastname: Moon
authors.forename: D S
authors.initials: DS
authors.lastname: Ryu
authors.forename: K K
authors.initials: KK
authors.lastname: Seo
authors.forename: D K
authors.initials: DK
authors.lastname: Kim
authors.forename: D S
authors.initials: DS
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007723:Korea; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D010919:Placebos; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D010879:Piperazines; D010919:Placebos; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate